Last Price | 112.62 | Max Price | 120.96 |
Min Price | 102.12 | 1 Year return | 2.58 |
Sector | Health Care | Subsector | Health Care Eq. & Services |
Annual report 2017 |
Abbott (previously known as Abbott alkaloid Company) is well known pharmaceutical company listed in S&P 500. The company is having approximately 90,000 employees in over 130 countries. Abbott was founded in 1888 by Wallace C. Abbott and is having its headquarters in Abbott Park, a northern suburb of Chicago, Illinois.
Contact info:Street: 100 Abbott Park RoadZip Code: IL 600646400City: Abbott ParkCountry: USAPhone: (847) 9376100Website: www.abbott.comCEO: Miles D. WhiteCFO: Thomas C. Freyman
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 31,904 | 2,019,579 | 1.58 % |
2020 | 34,608 | 2,170,517 | 1.59 % |
2021 | 43,075 | 2,404,876 | 1.79 % |
2022 | 43,653 | 2,645,792 | 1.65 % |
2023 | 0 | 0 | 0.00 % |
Date Label | Bank Label | Stock Label | Advice Label | Price Label | Diff Label |
---|---|---|---|---|---|
September 22, 2014 | RBC Capital Markets | Abbott | Buy | 48.00 | -143.50 % |
Analysts expect over 2023 revenue increase Abbott
Analysts expect revenue increase Abbott
Analysts expect revenue increase Abbott
Analysts expect over 2021 rising revenue Abbott
2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|
The headquarter of Abbott is based in Abbott Park. The core activities of Abbott are in the pharmaceutical sector. Miles D. White manages the company as a CEO. Thomas C. Freyman runs the company as a CFO. The past 10 years the (international) industry gained at around 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-2016) there is a minus of 75 percent.
The period between December 2015 and December 2016 was a bad period for the investors. The stock lost almost 13 percent. Abbott' stock rose the past 5 years at around 44 percent. Abbott's revenues between 2011 and 2015 were far from constant and moved between 39,87 billion dollars and 20,41 billion dollars. The net results between 2011 and 2015 were far from constant and fluctuated between 4,73 billion dollars and 2,61 billion dollars.
The American company paid out dividends in the past 5 years. Over the past 5 years Abbott's dividend yield was at around 6,11 percent per year. Over the past 5 years the company raised it's dividends each year. Because of the yearly increased dividends Abbott can be called a kind of dividend aristocrat.
At the end of 2015 the American company had a balance sheet of 41,25 billion dollars. 20,04 billion dollars (48,58 percent of the total balance sheet) was financed by debt. Last year the pharmaceutical company's price/earnings-ratio (PE) was around 25. So the investors valued the stock at 25 times 2015' earnings per share. Based on the classical stock valuation theories the American stock can be seen as a value stock.
At the end of 2015 the market capitalization (the number of shares outstanding multiplied by the stock price) of the pharmaceutical company equaled around 63,56 billion dollars. At the end of 2015 around 1,47 billion stocks were listed.
All Abbott's financial reports are available here. More information about Abbott can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
20,405
|
20,853
|
27,390
|
30,578
|
31,904
|
34,608
|
Costs |
15,982
|
19,453
|
26,913
|
28,210
|
28,217
|
30,113
|
Profit |
4,423
|
1,400
|
477
|
2,368
|
3,687
|
4,495
|
Margin of profit |
21.68
|
6.71
|
1.74
|
7.74
|
11.56
|
12.99
|
ROI |
20.85
|
6.82
|
1.54
|
7.76
|
11.86
|
13.71
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
21,211
|
20,538
|
30,897
|
30,524
|
31,088
|
32,784
|
Debt |
20,036
|
32,128
|
45,353
|
36,649
|
36,799
|
39,764
|
Total assets |
41,247
|
52,666
|
76,250
|
67,173
|
67,887
|
72,548
|
Solvency |
51.42
|
39.00
|
40.52
|
45.44
|
45.79
|
45.19
|
Cash |
6,125
|
18,775
|
9,610
|
4,086
|
4,140
|
7,148
|
Cashflow |
2,966
|
3,203
|
5,570
|
6,300
|
6,136
|
7,901
|
Employees |
0
|
0
|
0
|
0
|
0
|
|
Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow / Debt |
0.15
|
0.10
|
0.12
|
0.17
|
0.17
|
0.20
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
44.91
|
38.41
|
57.07
|
72.33
|
86.86
|
Eps |
0.94
|
0.27
|
1.34
|
2.07
|
2.52
|
Price/earnings-ratio |
47.78
|
142.26
|
42.59
|
34.94
|
44.69
|
Dividend |
1.04
|
1.06
|
1.12
|
1.28
|
1.44
|
Dividend % |
2.32 %
|
2.76 %
|
1.96 %
|
1.77 %
|
1.28 %
|
Payout % |
1.11
|
3.93
|
0.84
|
0.62
|
0.57
|
Book value |
13.94
|
17.72
|
17.39
|
17.64
|
18.51
|
Market to book |
0.31
|
0.46
|
0.30
|
0.24
|
0.16
|
Cashflow per stock |
2.17
|
3.19
|
3.59
|
3.48
|
4.46
|
Stocks |
1,473
|
1,744
|
1,756
|
1,763
|
1,771
|
Market Cap |
66.146.56
|
66.971.77
|
100.193.23
|
127.481.63
|
199.475.92
|
Date
|
Price
|
---|---|
17 Dec 2024
|
112.62
|
10 Dec 2024
|
114.90
|
06 Dec 2024
|
115.59
|
03 Dec 2024
|
116.81
|
29 Nov 2024
|
118.95
|
27 Nov 2024
|
117.96
|
13 Nov 2024
|
116.44
|
08 Nov 2024
|
115.30
|
05 Nov 2024
|
117.65
|
31 Oct 2024
|
114.45
|
29 Oct 2024
|
114.07
|
23 Oct 2024
|
116.12
|
19 Oct 2024
|
119.39
|
16 Oct 2024
|
116.05
|
14 Oct 2024
|
116.12
|
05 Oct 2024
|
112.64
|
02 Oct 2024
|
113.56
|
27 Sep 2024
|
112.73
|
20 Sep 2024
|
114.15
|
17 Sep 2024
|
117.63
|
13 Sep 2024
|
116.83
|
28 Aug 2024
|
113.10
|
26 Aug 2024
|
112.69
|
23 Aug 2024
|
112.10
|
11 Aug 2024
|
108.71
|
07 Aug 2024
|
109.94
|
05 Aug 2024
|
111.31
|
01 Aug 2024
|
105.94
|
30 Jul 2024
|
104.77
|
26 Jul 2024
|
105.96
|